Martin J. S. Dyer, Beatriz Aldaz, Jesús María Hernández-Rivas, Ming-Qing Du, Thomas Tousseyn, Elena Campos-Sanchez, Jose A. Martinez-Climent, Xabier Agirre, Anton Parker, Shaowei Zhang, Victor Segura, Sara V. Merino-Cortes, Amaia Vilas-Zornoza, María José Calasanz, Takashi Akasaka, Jose L. Fernandez-Luna, Cyril Broccardo, Idoia Martin-Guerrero, Maria Joao Baptista, Isidro Sánchez-García, Marcos González, Xavier Sagaert, Péter Balogh, Reiner Siebert, Ari Melnick, Sarah Moody, Eloy F. Robles, David Oscier, Beatriz Bellosillo, Yolanda R. Carrasco, Ricardo García-Muñoz, Carlos Panizo, Felipe Prosper, María José Terol, Laura Macri-Pellizeri, César Cobaleda, Antonio Salar, Esther Pena, Antonio Ferrández, Laura Barrio, Joan Climent, Maria Mena-Varas, Pierre Brousset, Sergio Roa, Institut Universitaire de France, Hungarian Scientific Research Fund, Fundación Inocente Inocente, Worldwide Cancer Research, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Deutsche Krebshilfe, and Marie Curie International Incoming Fellowship
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2-3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. While Nkx2-3-deficient mice exhibit the absence of marginal-zone B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that leads to the development of tumours, faithfully recapitulating the principal clinical and biological features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhesion molecules (ICAM-1, MadCAM-1) and the chemokine receptor CXCR4. These molecules enhance migration, polarization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transformation through triggering NF-κB and PI3K-AKT pathways. This study implicates oncogenic NKX2-3 in lymphomagenesis, and provides a valid experimental mouse model for studying the biology and therapy of human marginal-zone B-cell lymphomas., Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness, FIS-PI12/00202 (to J.A.M.-C.), RTICC-RD12/0036/0063 (to J.A.M-C.), RTICC-RD12/0036/0068 (to M.J.C and F.P.), RTICC-RD12/0036/0022 (to J.L.F-L.), RTICC-RD12/ 0036/0070 (to J.C.), RTICC-RD12/0036/0010 (to B.B.), RTICC- RD12/0036/0044 (to M.J.B.) and RTICC-RD12/0036/0069 (to J.M.H.R. and M.G.); by Worldwide Cancer Research project grant 15-1322 (to J.A.M.-C., Y.R.C. and M.-Q.D.); by BFU2011-30097 (to Y.R.C); by MINECO SAF2013-45787-R and Marie Curie Programme FP7-PIIF-2012-328177 (to S.R.); by the French-Spanish CITTIL project (to F.P., X.A., J.A.M.-C., C.B. and P. Brousset); by SAF2012-32810, SAF2014-57791-REDC; PIE14/00066, BIO/SA32/ 14 and CSI001U14 (to I.S.G); by FIS-ISCIII projects PI13/00160 and PI14/00025, and Fundación Inocente Inocente (to C.C.); by Deutsche Krebshilfe, Molecular Mechanisms in Malignant Lymphomas Network Project (to R.S.); by the Institut Universitaire de France (to P. Brousset); by the Broad Medical Research Program of The Eli and Edythe Broad Foundation and the Hungarian Scientific Research Fund (OTKA K108429) (to P. Balogh)